Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice

George M. Alley, Jason A. Bailey, DeMao Chen, Balmiki Ray, Lakshman K. Puli, Heikki Tanila, Pradeep K. Banerjee, Debomoy Lahiri

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-β peptides (Aβ) occurs as a result of aberrant processing of the full-length Aβ precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Aβ and improves cognition in transgenic mice with high brain levels of Aβ. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Aβ production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 μM), decreased levels of secreted APP and Aβ1-40. Levels of the potentially amylodogenic Aβ1-42 were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Aβ1-42 secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Aβ1-42, oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 μM and significantly reduced the cortical levels of soluble Aβ1-42. The ratio of Aβ1-40/Aβ1-42 increased in treated mice, suggesting effects on the γ-secretase complex. Thus, memantine reduces the levels of Aβ peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Aβ in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Aβ level has therapeutic implications for neurodegenerative disorders.

Original languageEnglish
Pages (from-to)143-154
Number of pages12
JournalJournal of Neuroscience Research
Volume88
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Presenilin-1
Memantine
Protein Precursors
Amyloid
Transgenic Mice
Peptides
Neuroblastoma
Alzheimer Disease
Brain
Amyloid Precursor Protein Secretases
Aptitude
Poisons
Therapeutics
N-Methyl-D-Aspartate Receptors
Neurodegenerative Diseases
Cognition
Cell Survival

Keywords

  • Aging
  • Cortex
  • Dementia
  • Lysosome
  • Membrane
  • Memory
  • Tissue culture

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice. / Alley, George M.; Bailey, Jason A.; Chen, DeMao; Ray, Balmiki; Puli, Lakshman K.; Tanila, Heikki; Banerjee, Pradeep K.; Lahiri, Debomoy.

In: Journal of Neuroscience Research, Vol. 88, No. 1, 01.2010, p. 143-154.

Research output: Contribution to journalArticle

Alley, GM, Bailey, JA, Chen, D, Ray, B, Puli, LK, Tanila, H, Banerjee, PK & Lahiri, D 2010, 'Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice', Journal of Neuroscience Research, vol. 88, no. 1, pp. 143-154. https://doi.org/10.1002/jnr.22172
Alley, George M. ; Bailey, Jason A. ; Chen, DeMao ; Ray, Balmiki ; Puli, Lakshman K. ; Tanila, Heikki ; Banerjee, Pradeep K. ; Lahiri, Debomoy. / Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice. In: Journal of Neuroscience Research. 2010 ; Vol. 88, No. 1. pp. 143-154.
@article{27059bc0048f49dea1e8546b47b7b4c5,
title = "Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice",
abstract = "Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-β peptides (Aβ) occurs as a result of aberrant processing of the full-length Aβ precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Aβ and improves cognition in transgenic mice with high brain levels of Aβ. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Aβ production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 μM), decreased levels of secreted APP and Aβ1-40. Levels of the potentially amylodogenic Aβ1-42 were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Aβ1-42 secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Aβ1-42, oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 μM and significantly reduced the cortical levels of soluble Aβ1-42. The ratio of Aβ1-40/Aβ1-42 increased in treated mice, suggesting effects on the γ-secretase complex. Thus, memantine reduces the levels of Aβ peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Aβ in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Aβ level has therapeutic implications for neurodegenerative disorders.",
keywords = "Aging, Cortex, Dementia, Lysosome, Membrane, Memory, Tissue culture",
author = "Alley, {George M.} and Bailey, {Jason A.} and DeMao Chen and Balmiki Ray and Puli, {Lakshman K.} and Heikki Tanila and Banerjee, {Pradeep K.} and Debomoy Lahiri",
year = "2010",
month = "1",
doi = "10.1002/jnr.22172",
language = "English",
volume = "88",
pages = "143--154",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Memantine lowers amyloid-β peptide levels in neuronal cultures and in APP/PS1 transgenic mice

AU - Alley, George M.

AU - Bailey, Jason A.

AU - Chen, DeMao

AU - Ray, Balmiki

AU - Puli, Lakshman K.

AU - Tanila, Heikki

AU - Banerjee, Pradeep K.

AU - Lahiri, Debomoy

PY - 2010/1

Y1 - 2010/1

N2 - Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-β peptides (Aβ) occurs as a result of aberrant processing of the full-length Aβ precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Aβ and improves cognition in transgenic mice with high brain levels of Aβ. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Aβ production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 μM), decreased levels of secreted APP and Aβ1-40. Levels of the potentially amylodogenic Aβ1-42 were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Aβ1-42 secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Aβ1-42, oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 μM and significantly reduced the cortical levels of soluble Aβ1-42. The ratio of Aβ1-40/Aβ1-42 increased in treated mice, suggesting effects on the γ-secretase complex. Thus, memantine reduces the levels of Aβ peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Aβ in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Aβ level has therapeutic implications for neurodegenerative disorders.

AB - Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-β peptides (Aβ) occurs as a result of aberrant processing of the full-length Aβ precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Aβ and improves cognition in transgenic mice with high brain levels of Aβ. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Aβ production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 μM), decreased levels of secreted APP and Aβ1-40. Levels of the potentially amylodogenic Aβ1-42 were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Aβ1-42 secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Aβ1-42, oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 μM and significantly reduced the cortical levels of soluble Aβ1-42. The ratio of Aβ1-40/Aβ1-42 increased in treated mice, suggesting effects on the γ-secretase complex. Thus, memantine reduces the levels of Aβ peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Aβ in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Aβ level has therapeutic implications for neurodegenerative disorders.

KW - Aging

KW - Cortex

KW - Dementia

KW - Lysosome

KW - Membrane

KW - Memory

KW - Tissue culture

UR - http://www.scopus.com/inward/record.url?scp=73949151820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949151820&partnerID=8YFLogxK

U2 - 10.1002/jnr.22172

DO - 10.1002/jnr.22172

M3 - Article

VL - 88

SP - 143

EP - 154

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 1

ER -